Optibrium Introduces the Latest Release of StarDrop Featuring Card View, a Unique Freeform Environment
Optibrium, a developer of software for drug discovery, has released version 6.0 of its StarDrop software platform. This major new release introduces Card View, an intuitive and highly flexible environment to view and interact with compound data in the context of discovery projects. Card View provides a unique and highly visual way to interpret data on compounds and their relationships, clearly highlighting the best chemistries and optimisation strategies for drug discovery. The software further extends StarDrop’s capabilities to reduce the time and cost associated with delivering high quality drug candidates.
Card View presents compound structures and associated data on virtual cards that can be moved and organised with complete freedom, creating ‘links’ and ‘stacks’ to capture relationships and groupings. This enables researchers to explore data in a flexible and interactive way and organise compounds in a manner that mirrors their thought processes. The resulting cards and views can be conveniently annotated and copied to clearly share results and conclusions. Furthermore, Card View provides an ideal environment in which analyses, such as clustering or molecular matched pairs, can be applied to organise compounds and highlight patterns or features that guide further optimisation strategies.
Dr Matthew Segall, Optibrium’s CEO, commented: “Card View is a ground-breaking approach to exploring and organising compound data. It breaks free from the restrictions of chemical spreadsheets and the traditional form views that often make it difficult to find optimal compounds and key structure-activity relationships. Feedback from customers has been overwhelmingly positive, as this novel environment brings researchers a new and interesting dimension in intuitive compound design.”
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.